BioCentury | Jul 14, 2020
Product Development

Moderna, NIH pick Phase III COVID-19 vaccine dose, show off highest neutralizing titers to date

Moderna revealed on Tuesday that prime-boost administration of low and medium doses of its COVID-19 vaccine induced the highest neutralization titers reported in humans to date, as well as a T cell response. The company...
BioCentury | Jul 9, 2020
Product Development

CSL testing coagulation factor blocker in COVID-19 patients; plus vaccine deals and plasma trials

As partnerships aimed at preventing COVID-19 or treating early disease continue to form and expand, CSL has begun testing a blood coagulation factor inhibitor for severe COVID-19. The CSL Behring unit of CSL Ltd. (ASX:CSL)...
BioCentury | Jun 20, 2020
Deals

Clinical scorecard for COVID-19: lessons from the first wave of controlled trials

Breaking through the noise of poor-quality clinical studies are the first clear signals of a treatment paradigm for COVID-19, indicating how and when to use the two major therapeutic approaches -- attacking the virus and...
BioCentury | Jun 16, 2020
Product Development

Sinovac COVID-19 vaccine yields neutralizing antibodies in Phase II, titers not revealed

Sinovac’s disclosure over the weekend of early clinical data from its COVID-19 vaccine makes it the third company to demonstrate production of neutralizing antibodies in humans, behind Moderna and CanSino. Sinovac’s data come from many...
BioCentury | Apr 24, 2020
Finance

Big gain for ORIC in trading debut after pricing upsized IPO

By posting a big gain Friday after pricing an upsized IPO at the top end of its range, ORIC provided another encouraging data point to biotechs seeking to test the public markets, suggesting that investors...
BioCentury | Apr 22, 2020
Finance

April 21 Financial Quick Takes: ORIC’s IPO plans; plus venture rounds for Magpie, Cloudbreak, ReAlta, New Horizon, Zikani

ORIC sets terms for planned IPO In an updated prospectus, oncology company ORIC Pharmaceuticals Inc. proposed to sell 5 million shares at $14-$16 in a planned IPO on NASDAQ. At the midpoint, a sale of...
BioCentury | Mar 26, 2020
Regulation

China’s NMPA suspends Abraxane imports after U.S. inspection

China’s suspension of the importation and sale of Celgene’s Abraxane by BeiGene following an inspection at a U.S. manufacturing site demonstrates how far the country has come in its drive to ensure safety of drugs,...
BioCentury | Jan 23, 2020
Politics & Policy

MNCs lead price cuts in China’s second round of centralized procurement

MNC originators took the deepest price cuts in the second round of China’s expanded centralized procurement program for generic and off-patent drugs. A list released Tuesday by China’s Joint Procurement Office showed that 77 winning...
BioCentury | Jan 22, 2020
Clinical News

BeiGene gearing up for PD-1 competition with Merck, Innovent in 1L squamous NSCLC in China

BeiGene announced Tuesday that tislelizumab met the primary endpoint in a Chinese Phase III trial for first-line squamous non-small cell lung cancer. The readout keeps BeiGene’s PD-1 mAb on track as it vies with Innovent’s...
BioCentury | Jan 7, 2020
Company News

BeiGene looks to carve out niche in China for tislelizumab

As it looks to roll out what will be at least the sixth marketed PD-1 inhibitor in China, BeiGene hopes the therapy’s differentiated efficacy profile and commercial infrastructure will help the company carve a niche...
Items per page:
1 - 10 of 371